期刊文献+

P63,34βE12,survivin,COX-2表达在乳腺良恶性上皮性病变鉴别诊断中的意义 被引量:1

下载PDF
导出
摘要 目的探讨肌上皮标记物P63、高分子细胞角蛋白34βE12、凋亡抑制蛋白survivin、环氧化酶(COX-2)在乳腺良恶性上皮性病变鉴别诊断中的意义。方法用免疫组织化学法(S-P)检测肌上皮标记物P63、高分子细胞角蛋白34βE12、凋亡抑制蛋白survivin及环氧化酶(COX-2)在50例普通性导管增生(UDH)、53例不典型导管增生(ADH)、58例导管内癌(DCIS),63例浸润性癌(IDC)中的表达,分析其与乳腺良恶性上皮性病变的关系及意义。结果在50例普通性导管增生(UDH),53例不典型导管增生(ADH),58例导管内癌,肌上皮表达均为阳性,63例浸润性癌,肌上皮均为阴性。34βE12的表达率及其强度在良性病变与癌组间,差异有显著性(P<0.05)。在良性病变与癌组之间,survivin,COX-2阳性表达率及表达程度差异有显著性(P<0.05)。结论P63,34βE12可作为乳腺病变鉴别诊断中良性病变的标记物,而survivin、COX-2阳性表达,有助于良恶性病变的鉴别。
出处 《广东医学》 CAS CSCD 北大核心 2007年第4期604-606,共3页 Guangdong Medical Journal
基金 广东省韶关市科技计划项目[编号:韶科(卫)2006-21]
  • 相关文献

参考文献9

二级参考文献37

  • 1[1]Nayar R, Breland C, Bedrossian U,et al. Immunoreactivity of ductal cells with putative myoepithelial markers: A potential pitfall in breast carcinoma. Ann Diagn Pathol, 1999,3(3): 165~73.
  • 2[2]Wang X, Mori I, Tang W,et al. p63 expression in normal, hyperplastic and malignant breast tissues. Breast Cancer, 2002,9(3):216~9.
  • 3[3]Werling RW, Hwang H, Yaziji H,et al. Immunohistochemical distinction of invasive from noninvasive breast lesions:A comparative study of p63 versus calponin and smooth muscle myosin heavy chain. Am J Surg Pathol, 2003,27(1):82~90.
  • 4[4]Ribeiro-Silva A, Zamzelli Ramalho LN, Garcia SB, et al. Is p63 reliable in detecting microinvasion in ductal carcinoma in situ of the breast? Pathol Oncol Res, 2003,9(1): 20~3.
  • 5Lerwill MF, Current practical applications of diagnostic immunohistochemistry in breast pathology [ J ]. Am J Surg Pathol,2004,28(8) : 1076 - 1091.
  • 6Sloane JP, Trott PA, Lakhani SR. Biopsy pathology of the breast[M] .2rd ed.London: Arnold,2001.2-4.
  • 7Rosen PP. Rosen' s breast pathology [ M ], 2rd ed. Philadelphia:Lippincott Williams & Wilkins.2001,1 - 19.
  • 8Dabbs DJ. Diagnostic immunohistochemistry[ M ]. New York: Churchill Livingstone, 2002.536 - 578.
  • 9Nayar R, Breland C, Bedrossian U, et al. Immunoreactivity of ductal cells with putative myoepithelial markers: a potential pitfall in.breast carcinoma [J] .Ann Diagn Pathol,1999,3(3) : 165 - 173.
  • 10Werling RW, Hwang H, Yaziji H, et al.immunohistochemical of invasive from noninvasive breast lesions: a comparative study of p63 versus calponin and smooth muscle myosin heavy chain[J]. Am J Surg Pathol, 2003,27:82 - 90.

共引文献66

同被引文献6

  • 1Beesley MF,Mclaren KM.Cytokeratin19 and galectin-3inmunohistochemistry in the differential diagnosis of soli-tary thyroid nodules[J].Histopathology,2002,41(2):236-243.
  • 2Gown AM,Vogel AM.Monoclonal antibodies to humanintermediate filament proteins II distribution of filamentproteins in normal human tissues[J].Am J Pathol,1984,114(2):309-321.
  • 3Jarasch ED,Nagle RB,Kaufmann M,et a1.Differenti-al diagnosis of benign epithelial proliferations and carcino-mas of the breast using antibodies to cytokeratins[J].Hum Pathol,1998,19(3):276-289.
  • 4Okada Y,Osada M,Kurata S,et a1.p53 gene familyp5l(p63)-ncoded,secondary transactivator p51B(TAp63alpha)occurs without forming an immunoprecipi-table complex with MDM2 but responds to genotoxic stressby accumulation[J].Exp Cell Res,2002,276(2):194-200.
  • 5武忠弼 杨光华主编.中华外科病理学[M].北京:人民卫生出版社,2002.646.
  • 6狄方,王念黎.细胞角蛋白34βE12在鉴别乳腺良、恶性病变中的意义[J].中华病理学杂志,2004,33(1):31-35. 被引量:9

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部